Autobahn Therapeutics announced a $100M series C this week as it prepares to move its thyromimetic into phase 2 for MDD and bipolar disorder depression

blonca9
Jul 26, 2024
1 min read

CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry platform. Plus, how the funding will also allow the company to advance a S1P receptor modulator.

Recent Posts

See All

Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data

ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

Autobahn Therapeutics announced a $100M series C this week as it prepares to move its thyromimetic into phase 2 for MDD and bipolar disorder depression

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight